Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 14/20 | 0.55 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | STAT1 | P42224 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | APC | P25054 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10278972 | 0.85 | F2R (0.56) | F2RFKBP1ANPC1MAPTSTAT1 | |
| SCHEMBL10278945 | 0.85 | F2R (0.58) | F2RFKBP1AMCHR1NPC1MAPT | |
| SCHEMBL10278685 | 0.79 | F2R (0.55) | F2RAKR1C3CNR1TMEM97 | |
| SCHEMBL10279061 | 0.78 | F2R (0.54) | F2RNPC1MAPTSTAT1RAB9A | |
| SCHEMBL10278739 | 0.76 | F2R (0.50) | F2RFKBP1AAKR1C3CNR1TMEM97 | |
| SCHEMBL641492 | 0.76 | F2R (0.53) | F2RFKBP1AAPC | |
| SCHEMBL10279026 | 0.76 | F2R (0.55) | F2RSMN1; SMN2AKR1C3CNR1TMEM97 | |
| SCHEMBL10279059 | 0.75 | F2R (0.53) | F2RAKR1C3 | |
| SCHEMBL485847 | 0.75 | F2R (0.69) | F2RFKBP1AMCHR1NPC1MAPT | |
| SCHEMBL3796710 | 0.74 | F2R (0.65) | F2RFKBP1AMCHR1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | F2R 698/4885FKBP1A 1760/4885MCHR1 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.